ArticleBiotechnology letters2025
Potential applications of lactic acid bacteria from Egyptian dairy products as novel antioxidant and anticancer agents.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral scientific studies have revealed the role of probiotic lactic acid bacteria and their metabolites, including antioxidant activity, which is required for reducing oxidative stress, and have implications for cancer treatment. This study evaluated the ability of isolates to exert antioxidative and in vitro anti-tumor effects against the HCT-116 colon cancer cell line, with fewer side effects compared to chemotherapy.
methodsThe in vitro antioxidative capacity of LAB isolates was quantified against DPPH free radicals. The cytotoxicity effects against the HCT-116 cells were analyzed using the MTT assay, microscopic fluorescence, flow cytometry, and qRT-PCR analysis of immunomodulatory cytokines and cancer-related gene expression.
resultsSeven LAB isolates exhibited potent antioxidant activity, scavenging 51.20 to 78.29% of DPPH free radicals. Lactobacillus delbrueckii subsp. bulgaricus (RE 254) demonstrated superior activity, with 78.29% scavenging and a ferric-reducing activity power of 38.04%. Conversely, Lactiplantibacillus plantarum (RE 298) showed 53.67% and 16.08% activity, respectively. At a concentration of 25 × 10
conclusionThe findings strongly suggest that RE 254 and RE 298 are compelling candidates for use as functional supplements and adjunctive therapeutics in colon cancer management. Their efficacy, demonstrated through multifaceted anti-tumor mechanisms, warrants further validation through in vivo studies to assess their clinical potential.
Indexed as
Identifiers
40965691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.